– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate the belrestotug development program – iTeos has initiated a targeted review of strategic alternatives to maximize shareholder value May 13, 2025 -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncolo

- Data support planned dosing regimen and protocol for FIH study to initiate in mid-2025 May 13, 2025 -- Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity, announced the presentation of new preclinical data in two poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, which is being held from May 13-17, 2025 in New Orleans, LA. The two poster presentations include data that

First small molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology Statistically significant improvements in T cell and psoriasis-related biomarkers in line with PASI improvements in Phase 2a in patients with psoriasis Results further confirm well-tolerated safety profile, with no serious adverse events or discontinuations May 09, 2025 -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmun

May 09, 2025 -- Garuda Therapeutics (“Garuda”), a biotechnology company developing off-the-shelf hematopoietic stem cell (HSC) therapies, today announced that it has changed its name to Stratus Therapeutics, Inc. (“Stratus”). The new name reflects the company’s commitment to pioneering full hematopoietic system renewal through its novel platform, Stratus Prime™, and lead product candidate, ST-101. Stratus Therapeutics is the only company developing on-demand Prime HSCs™ and Prime HPCs™ to rest

May 09, 2025 -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City.

May 09, 2025 -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, presented results from the Phase 2b SYMMETRY trial demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by metabolic dysfunction-associated steatohepatitis (MASH), in a late-breaking oral presentation at the European Association for the Study o

Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. May 09, 2025 -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead ass

May 09, 2025 -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, today announced results of a PET scan showing a marked reduction in microglia activation associated with neuroinflammation in a patient suffering from moderate Alzheimer's disease (AD) who was treated for three months with intranasa

Prof. Lars Zender’s featured talk described HepaRegeniX’s lead candidate and its potential in increasing liver regeneration, from initial target discovery and drug development towards Phase Ia clinical trial results May 8, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, announced that the company’s co-founder, Prof. Dr. med. Lars Zender, gave the Karl Wilhelm von Kupffer Basic Science State-of-the-Art plenary

New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. May 08, 2025 -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces the filing of a new composition of matter patent covering a novel solid form of AZD5904, a clinical-stage myeloper